Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | G6PD | P11413 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31009352 | 1.00 | LMNA (0.47) | LMNAKMT2AMAPK1MAPTMEN1 | |
| SCHEMBL18876048 | 0.79 | TSHR (0.47) | LMNAKMT2AMAPTMEN1KDM4E | |
| SCHEMBL6445623 | 0.77 | ATM (0.43) | LMNAMAPK1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL31009379 | 0.76 | HSP90AA1 (0.46) | LMNAKMT2AMAPK1MAPTMEN1 | |
| SCHEMBL1059436 | 0.76 | GPR35 (0.48) | LMNAKMT2AMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL31009443 | 0.76 | KIF11 (0.41) | LMNAKMT2AMAPK1MAPTMEN1 | |
| SCHEMBL29433461 | 0.74 | MAPT (0.42) | KMT2AMAPK1MAPTMEN1ALDH1A1 | |
| SCHEMBL10044955 | 0.73 | CYP3A4 (0.42) | LMNAKMT2AMAPK1MAPTMEN1 | |
| SCHEMBL4984623 | 0.73 | MAOA (0.42) | LMNAKMT2AMAPK1MAPTMEN1 | |
| SCHEMBL28792255 | 0.73 | CYP3A4 (0.47) | LMNAKMT2AMAPK1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117500786-A | TEAD inhibitors | 奥赖恩公司 | 2024-02-02 | — | — | CN | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | US | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | LMNA 2968/4885KMT2A 1939/4885MAPK1 38/4885 |
| US-20040048881-A1 | Quinazoline derivatives with anti-tumour activity | TOP1, NQO2, ABCC1 | LMNA 1099/4885KMT2A 2442/4885MAPK1 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.